Anti-Mouse CD5 (Lyt-1) – Purified No Carrier Protein
Anti-Mouse CD5 (Lyt-1) – Purified No Carrier Protein
Product No.: C3122
- -
- -
Clone 53-7.3 Target CD5 (Lyt-1) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names LY-1, T1, Tp67
Isotype Rat IgG2a κ Applications FC , IHC , IP |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Immunogen Mouse thymus or spleen Product Concentration 0.5 mg/ml Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. State of Matter Liquid
Storage and Handling This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? IHC, IP, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity 53-7.3 activity is directed against mouse CD5 (Lyt-1). Background CD5 (Lyt-1) is fundamental to immune homeostasis and immune tolerance, with many functions in T and B cells1. CD5 acts as a modulator of T and B cell receptor signaling as well as a cell survival receptor in T and B cells. CD5 is also involved in thymocyte selection, T cell effector differentiation, induces regulatory T cells in the periphery, and modulates Th17 and Th2 differentiation as well as dendritic cell function. Because of its role as an immune checkpoint modulator, CD5 is a target of immunotherapy in the treatment of cancer, autoimmune disease, and infection. 53-7.3 was generated by immunizing LOU/Ws1/M rats with mouse (SJL/J or C3H/HeJ) spleen cells or thymocyte membranes2. Spleen cells were subsequently fused with mouse myeloma NS-1 to produce a hybridoma. The antigen target CD5 (Lyt-1) was confirmed by comparative immunoprecipitation as well as blocking experiments using conventional alloantisera. Antigen Distribution CD5 (Lyt-1) is a marker used to identify T cells, B1-a cells, B cell chronic lymphocytic leukemia cells, regulatory T cell (Tregs), regulatory B cells (IL-10 producing Bregs), and the earliest thymic progenitors. CD5 is also expressed on all lymphocytes except natural killer cells. Ligand/Receptor CD72, gp35-37 NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology References & Citations1. Burgueño-Bucio E, Mier-Aguilar CA, Soldevila G. J Leukoc Biol. 105(5):891-904. 2019. 2. Ledbetter JA, Rouse RV, Micklem HS, et al. J Exp Med. 152(2):280-295. 1980. 3. Lanier LL, Warner NL, Ledbetter JA, et al. J Exp Med. 153(4):998-1003. 1981. 4. Ledbetter JA, Evans RL, Lipinski M, et al. J Exp Med. 153(2):310-323. 1981. 5. Hollander N. J Immunol. 133(5):2801-2805. 1984. 6. Hollander N, Pillemer E, Weissman IL. Proc Natl Acad Sci U S A. 78(2):1148-1151. 1981. 7. Stanton T, Stevens TL, Ledbetter JA, et al. J Immunol. 136(5):1734-1737. 1986. 8. Capasso M, Bhamrah MK, Henley T, et al. Nat Immunol. 11(3):265-272. 2010. 9. Wang JY, Lee J, Yan M, et al. Am J Pathol. 178(5):2168-2176. 2011. 10. Hu T, Ghazaryan S, Sy C, et al. Blood. 119(19):4532-4542. 2012. 11. Nakajima K, Maekawa Y, Kataoka K, et al. Nat Commun. 4:2112. 2013. 12. Ballas ZK, Buchta CM, Rosean TR, et al. PLoS One. 8(6):e65599. 2013. 13. Hogan T, Shuvaev A, Commenges D, et al. J Immunol. 190(8):3985-3993. 2013. 14. Reynolds C, Chong D, Raynsford E, et al. BMC Biol. 12:32. 2014. 15. Ying W, Tseng A, Chang RC, et al. Sci Rep. 6:20176. 2016. 16. Alrefai H, Muhammad K, Rudolf R, et al. Nat Commun. 7:11724. 2016. 17. Dutton EE, Camelo A, Sleeman M, et al. Wellcome Open Res. 2:117. 2017. 18. Freitas CMT, Hamblin GJ, Raymond CM, et al. PLoS One. 12(5):e0178799. 2017. 19. Early M, Schroeder WG, Unnithan R, et al. PeerJ. 5:e3555. 2017. 20. Hewitt KJ, Katsumura KR, Matson DR, et al. Dev Cell. 42(3):213-225.e4. 2017. 21. Kulkarni U, Herrmenau C, Win SJ, et al. PLoS One. 13(2):e0192304. 2018. 22. Lai D, Tang J, Chen L, et al. Cell Death Dis. 9(3):369. 2018. 23. Levy Y, Vagima Y, Tidhar A, et al. NPJ Vaccines. 3:52. 2018. 24. Moretti FA, Klapproth S, Ruppert R, et al. Elife. 7:e35816. 2018. 25. Niemeyer BF, Oko LM, Medina EM, et al. J Virol. 92(6):e01604-17. 2018. 26. Soukup AA, Zheng Y, Mehta C, et al. J Clin Invest. 129(3):1180-1192. 2019. 27. Ercoli G, Ramos-Sevillano E, Nakajima R, et al. Front Immunol. 11:611661. 2021. 28. Gilchrist AE, Harley BAC. Integr Biol (Camb). 12(7):175-187. 2020. 29. Pastrana-Otero I, Majumdar S, Gilchrist AE, et al. Analyst. 145(21):7030-7039. 2020. 30. Ngo MT, Barnhouse VR, Gilchrist AE, et al. Adv Funct Mater. 31(51):2101541. 2021. 31. Gilchrist AE, Serrano JF, Ngo MT, et al. Acta Biomater. 131:138-148. 2021. 32. Park JS, Lee D, Yang S, et al. J Transl Med. 20(1):85. 2022. 33. Xu L, Wei C, Chen Y, et al. Nat Commun. 13(1):6881. 2022. 34. Azam Z, Sapra L, Baghel K, et al. Cells. 12(2):216. 2023. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
C3123 | |
C3126 | |
C3125 | |
C3122 |
![Disclaimer Alert Disclaimer Alert](/wp-content/themes/Avada-Child-Theme/disclaimer.jpg)